Science Closes $230M Series C Funding

Why It Matters

The infusion of capital positions Science to move a breakthrough visual prosthetic toward market, potentially reshaping treatment for retinal diseases and setting a precedent for commercial BCI devices.

Key Takeaways

• $230M Series C brings total funding to $490M.
• Funds target PRIMA BCI retinal implant commercialization.
• PRIMA restored vision in late-stage macular degeneration trials.
• CE‑mark filing in EU; FDA approval pending.
• Clinical trial expansion includes Stargardt disease and retinitis pigmentosa.

Pulse Analysis

Science’s $230 million Series C underscores the rapid escalation of venture interest in neural engineering, a sector projected to exceed $30 billion by 2030. Investors such as Lightspeed and Khosla recognize the strategic advantage of a vertically integrated model that controls hardware, software, and manufacturing pipelines. By consolidating these capabilities, Science can shorten development cycles, reduce cost of goods, and protect intellectual property—critical factors as the market shifts from academic prototypes to scalable medical devices.

The PRIMA retinal implant represents a tangible milestone in brain‑computer interface (BCI) therapeutics. Clinical data published in the New England Journal of Medicine demonstrated restored functional vision for patients with advanced macular degeneration, a result that garnered mainstream attention on Time’s cover. This validation not only accelerates regulatory pathways—evidenced by the pending CE‑mark and FDA submissions—but also builds credibility for future indications, including Stargardt disease and retinitis pigmentosa. The upcoming European launch will provide real‑world performance metrics, informing pricing, reimbursement, and broader adoption strategies.

For the broader industry, Science’s progress signals a turning point where BCI technologies transition from experimental to commercial realities. Competitors in neuroprosthetics and visual restoration will need to match Science’s pace in clinical validation and regulatory compliance. Moreover, the infusion of nearly half‑billion dollars in capital highlights a growing confidence that neural interfaces can generate sustainable revenue streams, attracting further institutional investment and potentially spurring partnerships with ophthalmology groups, insurers, and technology platforms seeking to integrate neural data streams into next‑generation health solutions.